Clinical Trial Update: Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating suvorexant, a hypocretin antagonist, for restless legs syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Suvorexant (suvorexant)

Snippet

Sponsor: Diego García-Borreguero, MD, PhD | Conditions: Restless Legs Syndrome | Phase 2 | Status: UNKNOWN